Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacilac ORS
- Development stage
- Unknown
- Lead developer
- Ceres Pharma
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacilac ORS is a combined oral rehydration solution (ORS) and probiotic dietary supplement developed by Vesale Pharma. It is designed for the management of dehydration and the restoration of intestinal flora in infants, children, and adults suffering from acute diarrhea or fluid loss. The formulation consists of a specific balance of electrolytes (sodium chloride, potassium chloride, and trisodium citrate) and glucose, which facilitates the active transport of water across the intestinal epithelium via the sodium-glucose cotransporter. Additionally, it contains the probiotic strains *Lactobacillus rhamnosus* GG and *Bifidobacterium lactis*, which help re-establish a healthy gut microbiome. The product is supplied as a powder in sachets for reconstitution with water.
- Brand names
- Bacilac ORS
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on Bacilac ORS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacilac ORS.